DWC 20161
Alternative Names: DWC-20161Latest Information Update: 28 Oct 2019
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea
- 02 Nov 2016 Daewoong Pharmaceutical completes a phase I trial in Undefined indication (In volunteers) in South Korea (unspecified route) (NCT02947139)
- 01 Sep 2016 Phase-I clinical trials in Undefined indication (In volunteers) in South Korea (unspecified route) (NCT02947139)